|
|
 |
|
Viewing report
|
|
|
|
Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy
Datamonitor, Dec 2004, Pages: 236
This report provides you with:
- Capabilities and portfolio analysis of the top 20 generics companies operating in the US, Germany, UK, France, Spain and Italy
- Case study-based insight into the effectiveness of 15 portfolio management, marketing and growth strategies available to generics players
- Strategic profiles of 20 leading generics companies, including growth strategy, competitive positioning and alliance network analysis
- Analysis of the country-specific patent expiries for global blockbuster drugs
With cost-containment, a focus for all healthcare payers, the growth of the generics market is outpacing the branded sector by a considerable margin. However, the operating environment for generics is becoming increasingly competitive pushing existing players further up the pharmaceutical value chain. Brand and generics companies alike must be prepared for this new competition.
The Global Generics Guide Third Edition: Benchmarking Generics Company Capabilities and Strategy provides in-depth analysis and insight into the current and future competitive environment within the generics markets of the US, UK, Germany, France, Spain and Italy. Based on comprehensive analysis of the capabilities and portfolios of the leading players in each market, Datamonitor maps the competitive landscape for generic versions of multiple formulation types in each country. Effective evaluation of the competitive environment facing your brand or generic is critical to successful strategic planning.
Key findings and highlights:
- With 79.7% of 2003 blockbuster sales potentially exposed to generic competition by 2010, equating to $103.7 billion worth of products at 2003 sales value, the growth opportunities in the generics sector are significant. However, understanding how different country dynamics shape the competitive landscape is critical to evaluating risk and return.
- Effective portfolio management is critical to future success in the generics market. Maintaining breadth of portfolio and low cost supply is critical for commodity generics players, forcing many players to evaluate higher value generic sectors, thus generating new competitors to brand pharma.
- In the US, the generic injectables sector retains high barriers to entry, but in Europe, competitive analysis suggests that the market place is more crowded. As such, injectable products may represent a less valuable proposition to European generics players than US analysis would suggest.
Reasons to buy
- Identify the optimal portfolio management strategy for your company and the implications of those of your rivals
- Identify the likely rivals to your brand or generic in each of the six major markets
- Assess the implications of generics company strategic development on the success of your late-stage lifecycle management strategies
'...Successful players in the commodity generics markets must balance a broad portfolio with maximum geographic reach to generate economies of scale, while managing cost-effective producing and sourcing with a strong corporate brand image...'
Customers who bought this item also bought
Generics: Global Industry Guide
Generics Series: Authorized Generics Analysis
Generics Series: Generics Trends in the Seven Major Markets and Beyond
Global Generics Industry Report
Mylan: PharmaVitae Generics Profile
New Dynamics and Challenges in the Generics Market 2007
Global Generics Guide 2nd Edition: Optimizing Geographical and Strategic Positioning in an Evolving Generics Landscape
Generic Series: An Introduction To The Canadian Generics Market - Key Trends And Leading Companies Shaping The Market
Barr: PharmaVitae Generics Profile
Generics Series: Key trends and events in the 7 major markets
Partnering in the Global Generics Industry 2009: A Guide to Companies
Watson: PharmaVitae Generics Profile
|
|
|
|
